Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition - PubMed (original) (raw)
Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition
Jill M Brooks et al. J Immunol. 2009.
Abstract
CD8(+) T cells specific for EBV latent cycle epitopes can be reactivated in vitro by stimulating with the autologous EBV-transformed B lymphoblastoid cell line (LCL). The resultant CD8(+) clones kill epitope peptide-loaded targets, but frequently do not kill or show only low levels of lysis of the unmanipulated LCL in 5-h cytotoxicity assays. However, they reproducibly show clear LCL recognition in cytokine (IFN-gamma) release assays and inhibit LCL outgrowth in long-term coculture assays. We show that this growth inhibition is not mediated by cytokines, but by slow killing detectable in extended cytotoxicity assays. The paradoxical earlier findings reflect the fact that cytokine assays are more sensitive indicators of Ag-specific recognition in situations in which the target population is heterogeneous at the single-cell level in terms of epitope display. Such heterogeneity exists within LCLs with, at any one time, subpopulations showing large differences in sensitivity to T cell detection. These differences are not cell cycle related, but correlate with differing levels of EBV latent membrane protein (LMP)1 expression at the single-cell level. In this study, LMP1 is not itself a CD8(+) T cell target, but its expression enhances Ag-processing capacity and HLA class I expression. We propose that LMP1 levels fluctuate cyclically in individual cells and, over time, all cells within a LCL pass through a LMP1(high) T cell-detectable phase.
Similar articles
- CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
Khanolkar A, Fu Z, Underwood LJ, Bondurant KL, Rochford R, Cannon MJ. Khanolkar A, et al. J Immunol. 2003 Mar 15;170(6):3187-94. doi: 10.4049/jimmunol.170.6.3187. J Immunol. 2003. PMID: 12626577 - T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N. Nowakowska J, et al. Cytotherapy. 2015 Sep;17(9):1280-91. doi: 10.1016/j.jcyt.2015.06.003. Cytotherapy. 2015. PMID: 26276009 - EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines.
Haigh TA, Lin X, Jia H, Hui EP, Chan AT, Rickinson AB, Taylor GS. Haigh TA, et al. J Immunol. 2008 Feb 1;180(3):1643-54. doi: 10.4049/jimmunol.180.3.1643. J Immunol. 2008. PMID: 18209060 - Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C. Subklewe M, et al. J Exp Med. 2001 Feb 5;193(3):405-11. doi: 10.1084/jem.193.3.405. J Exp Med. 2001. PMID: 11157061 Free PMC article. - Role of LMP1 in immune control of EBV infection.
Pai S, Khanna R. Pai S, et al. Semin Cancer Biol. 2001 Dec;11(6):455-60. doi: 10.1006/scbi.2001.0412. Semin Cancer Biol. 2001. PMID: 11669607 Review.
Cited by
- Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
Messinger JE, Dai J, Stanland LJ, Price AM, Luftig MA. Messinger JE, et al. mBio. 2019 Jul 2;10(4):e01006-19. doi: 10.1128/mBio.01006-19. mBio. 2019. PMID: 31266868 Free PMC article. - Preparing Membrane Proteins for Simulation Using CHARMM-GUI.
Li Y, Liu J, Gumbart JC. Li Y, et al. Methods Mol Biol. 2021;2302:237-251. doi: 10.1007/978-1-0716-1394-8_13. Methods Mol Biol. 2021. PMID: 33877631 Free PMC article. - An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, Tang W, Burlingham WJ, Gulley ML, Kenney SC. Ma SD, et al. J Virol. 2012 Aug;86(15):7976-87. doi: 10.1128/JVI.00770-12. Epub 2012 May 23. J Virol. 2012. PMID: 22623780 Free PMC article. - Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.
Choi IK, Wang Z, Ke Q, Hong M, Qian Y, Zhao X, Liu Y, Kim HJ, Ritz J, Cantor H, Rajewsky K, Wucherpfennig KW, Zhang B. Choi IK, et al. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E686-E695. doi: 10.1073/pnas.1713607115. Epub 2018 Jan 8. Proc Natl Acad Sci U S A. 2018. PMID: 29311309 Free PMC article. - Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A, Plowshay J, Ma S, Nawandar D, Barlow EA, Romero-Masters JC, Bristol JA, Li Z, Tsai MH, Delecluse HJ, Kenney SC. Bilger A, et al. Oncotarget. 2017 Jul 4;8(27):44266-44280. doi: 10.18632/oncotarget.17863. Oncotarget. 2017. PMID: 28574826 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials